Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements

8 clinical trials · Condition

Record	Firm	Date
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma (NCT06649812)	National Cancer Institute (NCI)	2025-10-07
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NCT06536049)	Yazeed Sawalha	2025-04-02
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma (NCT05821088)	David Bond, MD	2023-06-29
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT05507541)	Mayo Clinic	2023-04-19
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma (NCT05755087)	Lapo Alinari	2023-03-06
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma (NCT05202782)	Northwestern University	2022-03-21
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (NCT03038672)	National Cancer Institute (NCI)	2018-12-21
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (NCT03103971)	Fred Hutchinson Cancer Center	2017-11-03

Every clearance here is in the API, with alerts when new ones post.